# Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

> **NCT05180097** · PHASE2 · RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 84 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Dexamethasone
- **DRUG:** Cisplatin
- **DRUG:** Brentuximab vedotin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05180097
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05180097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05180097, "Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05180097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*